Advanced Cardiac Therapeutics Completes Successful First-in-Man

« Back to Industry News


Advanced Cardiac Therapeutics, Inc., a developer and manufacturer of a proprietary and unique open-irrigated radio frequency (“RF”) ablation technology, tells us that its technology has been successfully used to treat 12 patients suffering from Atrial Fibrillation (“AFIB”) in Prague, Czech Republic.


Advanced Cardiac Therapeutics, Inc. (ACT) is a pre-commercial, medical device company that designs and manufactures a catheter-based system for the treatment of patients with AFIB. ACT’s technology is the only system in the world to leverage feedback from four unique capabilities: temperature sensing, low irrigation flow rates, high resolution EGM attenuation (to differentiate tissue types) and contact sensing.

The newly reported ACT first-in-man study was designed to evaluate the safety and effectiveness of the ACT system. The patients were treated by the study’s principal investigator, Dr. Vivek Reddy, Director of Cardiac Arrhythmia Services at Mount Sinai Hospital.

The study demonstrated that the four system features work in harmony to optimally control lesion formation, reduce ablation times and reduce infused fluid volumes. For the 12 patients, the safety end points were met and 100% acute success was achieved. In addition, the average “RF-on-time” per patient was 24 minutes and 49 seconds, the average ablation application duration was 17.1 seconds and, on average, these patients received only 406 ml of irrigation fluid during the entire Pulmonary Vein Isolation procedure.

Click here to view the full article.

« Back to Industry News